IMMUNOLOGIC MARKERS OF SEVERE REFRACTORY ATOPIC DERMATITIS

严重难治性特应性皮炎的免疫标志物

• 批准号: 7719404
• 负责人: DONALD YM LEUNG
• 金额: $ 0.26万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719404
• 关键词: Adult; Allergens; Atopic Dermatitis; Biopsy; Blood specimen; Child; Computer Retrieval of Information on Scientific Projects Database; Functional disorder; Funding; Future; Grant; Hydration status; Immune; Immune system; Immunologic Markers; Institution; Lead; Mycoses; Patients; Pharmaceutical Preparations; Refractory; Research; Research Personnel; Resistance; Resources; Skin; Source; United States National Institutes of Health; day; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Every year at NJMRC we see a subset of adult patients in our Day Program with severe atopic dermatitis that is resistant to most traditional therapies. Unlike their child counterparts, improvement in their skin is slow despite intensive hydration therapy and topical medications. We suspect that these patients may have significant dysfunction in the immune defenses of their skin that makes them more susceptible to the effects of bacterial and fungal infection, allergen sensitization. This study will involve taking skin bacterial cultures, skin biopsies and blood samples. An understanding of the underlying differences in the immune system of the skin in these patients may lead to future treatments for atopic dermatitis.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 每年在NJMRC，我们都会在我们的日间计划中看到一部分患有严重特应性皮炎的成人患者，这种皮炎对大多数传统疗法都有抵抗力。与他们的孩子不同，尽管进行了密集的补水治疗和局部药物治疗，但他们的皮肤改善缓慢。我们怀疑，这些患者的皮肤免疫防御功能可能存在严重障碍，这使得他们更容易受到细菌和真菌感染、过敏原致敏的影响。这项研究将包括采集皮肤细菌培养、皮肤活检和血液样本。了解这些患者皮肤免疫系统的潜在差异可能会导致未来特应性皮炎的治疗。